News

Phase 1 Study Shows Synergistic Anti-tumour Efficacy of Combination of New Drug and Chemotherapy for HCC, Warranting Further Phase II/III Studies

11/04/2022

× CLOSE

Phase 1 Study Shows Synergistic Anti-tumour Efficacy of Combination of New Drug and Chemotherapy for HCC, Warranting Further Phase II/III Studies

11/04/2022

[Pharma Tips] How to determine the dosing interval?

06/04/2022

× CLOSE

[Pharma Tips] How to determine the dosing interval?

06/04/2022

Do you follow the standard intervals indicated on the drug label and take your medicines on time? Why are some drugs only taken once daily, while some need to be taken for more than 4 times a day? Some people might also think that the more medicines one takes, the faster the recovery. Is it true?

Number of doses per day is affected by a bunch of factors, one of which is the metabolic rate of a drug in human body. If the metabolic rate is fast, the daily dose would be higher so as to maintain a steady drug concentration in your body. You should follow the instuctions and take the medications on time. Never take more or less medicines than prescribed. Overdose will cause toxicity, while insufficient dosage will affect the treatment.

The dosing interval is determined by the number of daily doses. Unless specified by your doctor, the dosing interval is as follows:

  • 1 time a day: Every 24 hours and taken at the same time every day
  • 2 times a day: Every 10-12 hours
  • 3 times a day: Every 6-8 hours
  • 4 times a day: Every 4-6 hours

 

[Study Completion] Successful Completion of Clinical Study for Sancuso® skin patch

20/12/2021

× CLOSE

[Study Completion] Successful Completion of Clinical Study for Sancuso® skin patch

20/12/2021

[Centre News] International Clinical Trial Center Network (ICN) Steering Board Meeting and Annual General Meeting 2021

18/11/2021

× CLOSE

[Centre News] International Clinical Trial Center Network (ICN) Steering Board Meeting and Annual General Meeting 2021

18/11/2021

The ICN Annual Steering Board Meeting 2021 took place on November 16, 2021 in the form of virtual meeting and was hosted by Cambridge Clinical Trials Unit (CCTU), Cambridge University Hospitals NHS Foundation Trust, one of the steering board members. During the meeting, all steering board members made decisions on key governance items. Mr. Henry Yau, ICN Chairperson cum Managing Director of HKU-CTC and Ms. Dr med Christiane Blankenstein, ICN Vice-Chairperson cum Director of Muenchner Studienzentrum, led the discussion on the strategic plan of ICN for the incoming year, which set out a direction for the Operations Team to work on in the year to come.

The ICN Annual General Meeting 2021 was held on November 17, 2021. Three experience sharing sessions were arranged and representatives from Cambridge University Hospitals and AstraZeneca were invited to talk about patient and public involvement as well as the influences of COVID-19 on clinical trials, which are both hot topics in 2021. Enthusiastic responses were received during the Q&A session. The next ICN Steering Board Meeting and Symposium will be hosted by Muenchner Studienzentrum, Technical University Munich, School of Medicine, in October 2022.

[Centre News] “A tour to HKU Phase 1 Clinical Trials Centre” Interview by Our Hong Kong Foundation

05/11/2021

× CLOSE

[Centre News] “A tour to HKU Phase 1 Clinical Trials Centre” Interview by Our Hong Kong Foundation

05/11/2021

Curious about our HKU Phase 1 Clinical Trials Centre? In the episode 1 of the interview, you will have a view of the Centre, and Mr. Henry Yau, our Managing Director, will also introduce HKU’s efforts and achievements in clinical research and novel drugs development.

https://www.youtube.com/watch?v=IWzwTAenZzA

In episode 2, you will know more about the strengths of Hong Kong in conducting clinical trials, as well as the challenges we need to overcome.

https://www.youtube.com/watch?v=LsT8brGP_F4

Phase 1 Study Proves Long-acting Formulation of Bupivacaine a Safe Means to Relieve Post-surgical Pain

29/09/2021

× CLOSE

Phase 1 Study Proves Long-acting Formulation of Bupivacaine a Safe Means to Relieve Post-surgical Pain

29/09/2021

[HKU-CTC PUBLIC EDUCATION SERIES] Chapter 3: The Importance of Phase 1 Clinical Trials

17/09/2021

× CLOSE

[HKU-CTC PUBLIC EDUCATION SERIES] Chapter 3: The Importance of Phase 1 Clinical Trials

17/09/2021

A new chapter of HKU-CTC Public Education Series named “The Importance of Phase 1 Clinical Trials” was posted on HKU-CTC Facebook page on September 17, 2021.

[Study News] Now News Report: Phase 1 clinical trial of HKU intranasal COVID-19 vaccine has commenced (May 15, 2021)

10/06/2021

× CLOSE

[Study News] Now News Report: Phase 1 clinical trial of HKU intranasal COVID-19 vaccine has commenced (May 15, 2021)

10/06/2021

Now News visited HKU Phase 1 Clinical Trials Centre earlier to produce a report on the process and progress of the phase 1 clinical trial of “VectorFlu ONE”. Here is the report by Now News (Chinese only):

Natural phytosterols prove to lower the low-density lipoprotein level and may reduce the risk of heart disease

24/05/2021

× CLOSE

Natural phytosterols prove to lower the low-density lipoprotein level and may reduce the risk of heart disease

24/05/2021

High cholesterol level is prevalent in Hong Kong. About half of the population have hypercholesterolemia. It is one of the major risk factor for cardiovascular diseases. Professor Bernard Cheung of HKU Department of Medicine and Dr. Ching-Lung Cheung of HKU Department of Pharmacy and Pharmacology conducted a 3-week clinical trial in 2015.

[Study News] Phase 1 clinical trial of VectorFlu ONE, COVID-19 nasal vaccine, has commenced!

14/05/2021

× CLOSE

[Study News] Phase 1 clinical trial of VectorFlu ONE, COVID-19 nasal vaccine, has commenced!

14/05/2021

The phase 1 clinical trial of VectorFluTM ONE, the world’s first COVID-19 nasal vaccine developed by the research team of HKU Department of Microbiology, has commenced in March 2021 at the HKU Phase 1 Clinical Trials Centre. About 115 healthy volunteers will be recruited to evaluate the safety and immune responses of the vaccine.

VectorFluTM ONE is the first novel vaccine that is developed by Hong Kong and goes into human trial. The phase 1 trial will last for around 1.5 years. Part 1 of the trial has commenced in March 2021, where about 30 volunteers have already received one or two vaccinations. Part 2 will begin in July 2021 and 85 volunteers will be recruited. We are still looking for more volunteers to join.